about
Impaired apoptosis, extended duration of immune responses, and a lupus-like autoimmune disease in IEX-1-transgenic miceCD95 (APO-1/Fas) linkage to the actin cytoskeleton through ezrin in human T lymphocytes: a novel regulatory mechanism of the CD95 apoptotic pathwayFas-ligand: privilege and perilRipped to deathSuppression of Fas-FasL coexpression by erythropoietin mediates erythroblast expansion during the erythropoietic stress response in vivoApoptosis and p53 expression in rat adjuvant arthritisSerum levels of autoantibodies against monomeric C-reactive protein are correlated with disease activity in systemic lupus erythematosusSexual dimorphism in immune response genes as a function of puberty.Dissecting immunity by germline mutagenesisViral infection and the evolution of caspase 8-regulated apoptotic and necrotic death pathwaysLack of both Fas ligand and perforin protects from flavivirus-mediated encephalitis in mice.Fas-Fas Ligand: Checkpoint of T Cell Functions in Multiple SclerosisColchicine protects mice from the lethal effect of an agonistic anti-Fas antibodyEnhanced T cell apoptosis in common variable immunodeficiency: negative role of the fas/fasligand system and of the Bcl-2 family proteins and possible role of TNF-RSGranule-dependent cytolysis of Mycobacterium tuberculosis-infected macrophages by human gammadelta+ T cells has no effect on intracellular mycobacterial viabilityAccelerating the induction of Fas-mediated T cell apoptosis: a strategy for transplant tolerance?TIPE2, a negative regulator of innate and adaptive immunity that maintains immune homeostasisFas antigen/CD-95 upregulation and activation during castration-induced regression of the rat ventral prostate glandAltered antigen receptor signaling and impaired Fas-mediated apoptosis of B cells in Lyn-deficient miceSevere destructive autoimmune lesions with aging in murine Sjögren's syndrome through Fas-mediated apoptosisT cells express a phagocyte-type NADPH oxidase that is activated after T cell receptor stimulationFas ligand is required for the development of respiratory syncytial virus vaccine-enhanced diseaseDistinct T cell receptor signaling requirements for perforin- or FasL-mediated cytotoxicity.Protein kinase D1/2 is involved in the maturation of multivesicular bodies and secretion of exosomes in T and B lymphocytesFas/Fas ligand-mediated apoptosis in different cell lineages and functional compartments of human lymph nodesTransgenes and knockout mutations in animal models of type 1 diabetes and multiple sclerosis.Genetic models of abnormal apoptosis in lymphocytes.Environmentally induced autoimmune diseases: potential mechanismsTh1 CD4+ lymphocytes delete activated macrophages through the Fas/APO-1 antigen pathway.Application of a Fas ligand encoding a recombinant adenovirus vector for prolongation of transgene expression.Expression and function of Fas during differentiation and activation of B cells.Pertinence of apoptosis markers for the improvement of in vitro fertilization (IVF)The immunomodulatory role of CD4-positive cytotoxic T-lymphocytes in health and disease.Apoptosis in human autoimmune diseases.Fas and Fas ligand in gut and liver.Target sites for manipulating apoptosis in prostate cancer.Negative autoregulation by Fas stabilizes adult erythropoiesis and accelerates its stress responseHormonal regulation of physiological cell turnover and apoptosis.Expression of Fas (CD95/APO-1) ligand by human breast cancers: significance for tumor immune privilegePhysiology of apoptosis.
P2860
Q24530757-166EAF9D-3130-4CB1-8518-FAFC5347A627Q24598098-A1B8E37D-6F24-4D5E-989A-FD87FE7EBB61Q24612227-F9DA3FFA-0F0A-4368-9BD4-D754E120BAC0Q24632980-66925708-C3C6-44B0-B0C4-08FA399508BAQ24685620-7C3FFD9C-EC9E-41C5-B4AE-2F5DB489FC48Q24792387-0A402780-80A3-48F5-A4E4-FBE602DBE28DQ24793357-DBD156B3-A601-4D00-9BE8-49E8184C25B0Q25257034-0B08724D-8139-4744-8BEA-C416281C0032Q27002466-67E83A89-8B2E-4BCB-B1B6-194DF3877252Q27010127-38448964-8FCE-4510-AC67-7ACA6F563AA1Q27472849-7A3E3DFD-8F1D-4E5A-A361-4752F9235AE3Q28074658-CCFA4DD6-CCC6-448C-9C07-6541F17E15C8Q28343905-EC1D0692-B5A5-4942-9BC6-BB562D86D183Q28344919-06BF4781-F057-4785-B936-F8111E8E56D0Q28362598-25AEDEE7-21CF-4C63-8CF3-2CB2E12CABB0Q28366005-DDC3EC19-CC23-4B3A-9020-AF5C6E4A91F0Q28509230-DFF79A41-D95A-4A13-9414-4894DB2294F4Q28574439-464CEC2A-EB0E-412F-B04D-946673F735F4Q28589721-F51594E5-48A4-4DB2-B6C3-34F93AA5DC84Q28590287-F334CFBF-5144-42F0-B682-38491731AF3EQ28595069-4EFF27EC-2A00-44AF-9C68-6059566FA8F3Q30436942-84F5C3C6-5230-4FBB-9363-5E7AC73D5E7BQ30442845-0587FF1E-269B-4696-9395-840FC84500F2Q30735300-F3962B8B-9F69-4EFE-AEFC-325E1373B6A9Q33579574-D3252CD7-3833-4228-9CED-41B9EECF0EC4Q33713298-7C64F11B-0052-44C9-875C-5A59DDE0FDDDQ33713368-D5FD8A7E-7D67-40CF-A0DC-04F1D6B9902AQ33741188-489FDDDD-A345-4C47-9154-D45F49C13AD6Q33766466-A69B03D4-4EE8-458C-AB6F-D0E74ABD825AQ33782516-B628F48A-E126-40AC-BA6A-379ECD345338Q33811744-ECC826E1-3381-4B7C-93F7-36BECB61DBB0Q33819236-210D6B0E-57EB-4A29-BF60-8E52DADCDD09Q33836317-5DC2BF37-110B-412C-A43C-4D8E955B31C2Q33836352-70D09AA6-B4C0-4A05-BAE3-E073F629C767Q33860215-5DD051FF-D121-4771-9EAC-491572C52F4FQ33898831-BE7F17E9-D672-4090-888A-983C747C4DB0Q33961430-935C2B5D-87F9-42F4-9024-A2EEB8BE9F7DQ33992348-72204E4B-70E3-4954-9AA7-9DF431583FC3Q33997713-D6C032E0-A3CA-4572-9EC1-46B709A568BDQ34039921-051902F2-C48D-4F59-85B2-02C2B3864306
P2860
description
1995 nî lūn-bûn
@nan
1995年の論文
@ja
1995年論文
@yue
1995年論文
@zh-hant
1995年論文
@zh-hk
1995年論文
@zh-mo
1995年論文
@zh-tw
1995年论文
@wuu
1995年论文
@zh
1995年论文
@zh-cn
name
Fas and Fas ligand: lpr and gld mutations.
@en
type
label
Fas and Fas ligand: lpr and gld mutations.
@en
prefLabel
Fas and Fas ligand: lpr and gld mutations.
@en
P1433
P1476
Fas and Fas ligand: lpr and gld mutations.
@en
P356
10.1016/0167-5699(95)80069-7
P577
1995-01-01T00:00:00Z